PATH vs PSTV · P/E 19, rev $1.61B vs P/E 0.2, rev $5.8M
Uipath Inc (PATH) versus Plus Therapeutics Inc (PSTV) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Plus Therapeutics Inc (PSTV) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PSTV revenue for 2024-12-31 was $5.8M. Net income was -$13.0M. Revenue was up 18.5% from 2023-12-31 to 2024-12-31. PSTV currently screens at market cap $29.7M and trailing P/E 0.2.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PSTV currently screens at market cap $29.7M and trailing P/E 0.2.
Not investment advice. Open the PATH and PSTV stock pages for the full models.
Not investment advice.